NIV-话题@MedSci

#NIV#

134篇内容 | 1234人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2007955, encodeId=7221200e955ea, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=Thorac Cancer：回顾性分析使用nivolumab治疗获得长期生存的NSCLC患者的相关因素, objectType=article, longId=293621, objectId=07a32936217f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=07a32936217f, replyNumber=0, likeNumber=48, createdTime=2022-01-28, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=07a32936217f, moduleTitle=Thorac Cancer：回顾性分析使用nivolumab治疗获得长期生存的NSCLC患者的相关因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=07a32936217f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007966, encodeId=2058200e96687, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=ASCO：NIVO+RELA相较NIVO能更好的的改善既往未经治疗的转移性或不可切除性黑色素瘤患者, objectType=article, longId=728227, objectId=6d23e28227bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d23e28227bf, replyNumber=0, likeNumber=51, createdTime=2022-08-30, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d23e28227bf, moduleTitle=ASCO：NIVO+RELA相较NIVO能更好的的改善既往未经治疗的转移性或不可切除性黑色素瘤患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6d23e28227bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007968, encodeId=7129200e968f1, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=Eur Urol：化放疗联合Nivolumab±Ipilimumab治疗肌层浸润性膀胱癌的安全性评估, objectType=article, longId=735447, objectId=b7ffe3544777, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b7ffe3544777, replyNumber=0, likeNumber=63, createdTime=2023-04-10, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b7ffe3544777, moduleTitle=Eur Urol：化放疗联合Nivolumab±Ipilimumab治疗肌层浸润性膀胱癌的安全性评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b7ffe3544777)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007949, encodeId=9588200e949f3, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=Clin Cancer Res：术前和术后应用nivolumab和lirilumab治疗局部区域复发的头颈部鳞状细胞癌(SCCHN)患者的疗效和安全性, objectType=article, longId=221221, objectId=5f1d221221eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5f1d221221eb, replyNumber=0, likeNumber=43, createdTime=2022-03-28, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5f1d221221eb, moduleTitle=Clin Cancer Res：术前和术后应用nivolumab和lirilumab治疗局部区域复发的头颈部鳞状细胞癌(SCCHN)患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5f1d221221eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007965, encodeId=3259200e9658f, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=2022 ASCO：RP1+nivo治疗皮肤癌的疗效与安全性——IGNYTE研究的最新结果, objectType=article, longId=728230, objectId=1cdae2823048, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1cdae2823048, replyNumber=0, likeNumber=57, createdTime=2023-01-19, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1cdae2823048, moduleTitle=2022 ASCO：RP1+nivo治疗皮肤癌的疗效与安全性——IGNYTE研究的最新结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1cdae2823048)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007959, encodeId=566a200e959dc, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=Eur Urol Focus：Nivolumab单药治疗晚期肾细胞癌的疗效如何？, objectType=article, longId=295417, objectId=c68f29541e66, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c68f29541e66, replyNumber=0, likeNumber=38, createdTime=2022-06-05, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c68f29541e66, moduleTitle=Eur Urol Focus：Nivolumab单药治疗晚期肾细胞癌的疗效如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c68f29541e66)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007967, encodeId=7581200e96774, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=Eur Urol：Bempegaldesleukin加Nivolumab用于一线转移性尿路上皮癌效果如何？, objectType=article, longId=730487, objectId=eb89e30487a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb89e30487a4, replyNumber=0, likeNumber=32, createdTime=2023-05-24, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb89e30487a4, moduleTitle=Eur Urol：Bempegaldesleukin加Nivolumab用于一线转移性尿路上皮癌效果如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eb89e30487a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007957, encodeId=2ede200e957fb, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=Ann Oncol：一线nivolumab + ipilimumab vs化疗治疗不可切除的恶性胸膜间皮瘤的疗效:CheckMate 743的3年生存结果, objectType=article, longId=295347, objectId=691929534ef4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=691929534ef4, replyNumber=0, likeNumber=43, createdTime=2022-10-16, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=691929534ef4, moduleTitle=Ann Oncol：一线nivolumab + ipilimumab vs化疗治疗不可切除的恶性胸膜间皮瘤的疗效:CheckMate 743的3年生存结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=691929534ef4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007963, encodeId=d9c0200e96356, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=FDA批准LAG-3抗体Relatlimab联合Nivolumab用于不可切除或转移性黑色素瘤的儿童和成人患者, objectType=article, longId=301197, objectId=1dfe30119ee0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1dfe30119ee0, replyNumber=0, likeNumber=51, createdTime=2022-07-15, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1dfe30119ee0, moduleTitle=FDA批准LAG-3抗体Relatlimab联合Nivolumab用于不可切除或转移性黑色素瘤的儿童和成人患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1dfe30119ee0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007953, encodeId=9ce9200e953eb, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=Clin Cancer Res：Nivolumab对比卡铂+培美曲塞治疗EGFR突变NSCLC患者一线TKI治疗进展后的疗效, objectType=article, longId=292260, objectId=b801292260d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b801292260d3, replyNumber=0, likeNumber=50, createdTime=2022-07-23, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b801292260d3, moduleTitle=Clin Cancer Res：Nivolumab对比卡铂+培美曲塞治疗EGFR突变NSCLC患者一线TKI治疗进展后的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b801292260d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007947, encodeId=97e2200e94786, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=Clin Cancer Res：nivolumab + ipilimumab对比舒尼替尼治疗晚期肾细胞癌（aRCC）患者后的无治疗生存时间（TFS）对比：来自Check- Mate 214研究结果, objectType=article, longId=220254, objectId=cfa922025489, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cfa922025489, replyNumber=0, likeNumber=43, createdTime=2021-12-18, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cfa922025489, moduleTitle=Clin Cancer Res：nivolumab + ipilimumab对比舒尼替尼治疗晚期肾细胞癌（aRCC）患者后的无治疗生存时间（TFS）对比：来自Check- Mate 214研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cfa922025489)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007942, encodeId=d457200e94266, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=NEJM：bamlanivimab-etesevimab双中和抗体疗法治疗轻中度新冠肺炎, objectType=article, longId=214302, objectId=2dec214302a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2dec214302a8, replyNumber=0, likeNumber=43, createdTime=2021-08-31, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2dec214302a8, moduleTitle=NEJM：bamlanivimab-etesevimab双中和抗体疗法治疗轻中度新冠肺炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2dec214302a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007961, encodeId=9684200e96178, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=J Immunother Cancer：CheckMate 920研究评估nivolumab(那武利尤单抗)+ ipilimumab (伊匹木单抗)治疗晚期非透明细胞肾癌患者的疗效和安全性, objectType=article, longId=299733, objectId=15e0299e3314, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=15e0299e3314, replyNumber=0, likeNumber=42, createdTime=2022-10-24, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=15e0299e3314, moduleTitle=J Immunother Cancer：CheckMate 920研究评估nivolumab(那武利尤单抗)+ ipilimumab (伊匹木单抗)治疗晚期非透明细胞肾癌患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=15e0299e3314)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007954, encodeId=e9e9200e95437, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=Ann Oncol：局限期小细胞肺癌(LD-SCLC)患者同步放化疗+PCI后使用nivolumab+ipilimumab免疫联合强化治疗并不能改善患者的预后, objectType=article, longId=292797, objectId=618f292e9792, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=618f292e9792, replyNumber=0, likeNumber=44, createdTime=2022-01-06, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=618f292e9792, moduleTitle=Ann Oncol：局限期小细胞肺癌(LD-SCLC)患者同步放化疗+PCI后使用nivolumab+ipilimumab免疫联合强化治疗并不能改善患者的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=618f292e9792)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007946, encodeId=a871200e946b2, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=J Immunother Cancer：黑素瘤脑转移(MBMs)患者一线BRAF- MEKi耐药后使用ipilimumab- nivolumab治疗效果差, objectType=article, longId=218646, objectId=e1fc218646bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e1fc218646bf, replyNumber=0, likeNumber=41, createdTime=2022-09-25, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e1fc218646bf, moduleTitle=J Immunother Cancer：黑素瘤脑转移(MBMs)患者一线BRAF- MEKi耐药后使用ipilimumab- nivolumab治疗效果差, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e1fc218646bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007939, encodeId=3191200e93990, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=Lung Cancer: 纳武利尤单抗（nivolumab）治疗既往治疗过的晚期NSCLC患者的2年生存：来自法国、德国和加拿大的真实世界研究, objectType=article, longId=213586, objectId=462521358613, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=462521358613, replyNumber=0, likeNumber=31, createdTime=2021-09-01, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=462521358613, moduleTitle=Lung Cancer: 纳武利尤单抗（nivolumab）治疗既往治疗过的晚期NSCLC患者的2年生存：来自法国、德国和加拿大的真实世界研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=462521358613)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007934, encodeId=86f4200e93481, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=Ann Oncol: 纳武利尤单抗（Nivolumab）二线治疗并不能改善小细胞肺癌的预后：来自CheckMate 331临床研究, objectType=article, longId=212154, objectId=c931212154fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c931212154fa, replyNumber=0, likeNumber=44, createdTime=2021-10-12, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c931212154fa, moduleTitle=Ann Oncol: 纳武利尤单抗（Nivolumab）二线治疗并不能改善小细胞肺癌的预后：来自CheckMate 331临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c931212154fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007962, encodeId=1e14200e96258, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=J Immunother Cancer：Nivolumab(那武利尤单抗)联合cabozantinib(卡博替尼)治疗晚期子宫内膜癌患者的疗效, objectType=article, longId=300936, objectId=cbcd3009360c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cbcd3009360c, replyNumber=0, likeNumber=45, createdTime=2022-08-01, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cbcd3009360c, moduleTitle=J Immunother Cancer：Nivolumab(那武利尤单抗)联合cabozantinib(卡博替尼)治疗晚期子宫内膜癌患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cbcd3009360c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007940, encodeId=0d3b200e940eb, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=Eur Urol：Nivolumab治疗转移性肾细胞癌的患者的原发性肾肿瘤反应 , objectType=article, longId=213725, objectId=ecda213e25ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ecda213e25ad, replyNumber=0, likeNumber=37, createdTime=2022-05-13, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ecda213e25ad, moduleTitle=Eur Urol：Nivolumab治疗转移性肾细胞癌的患者的原发性肾肿瘤反应 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ecda213e25ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007964, encodeId=6a55200e9645a, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=Clin Cancer Res：ATTRACTION-3研究3年随访生存结果表明nivolumab较化疗改善晚期食管鳞状细胞癌（ESCC）患者预后, objectType=article, longId=301417, objectId=e1c330141efe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e1c330141efe, replyNumber=0, likeNumber=48, createdTime=2023-01-06, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e1c330141efe, moduleTitle=Clin Cancer Res：ATTRACTION-3研究3年随访生存结果表明nivolumab较化疗改善晚期食管鳞状细胞癌（ESCC）患者预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e1c330141efe)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

NIV

2020-05-29

tamgche (审核中...)

前往app查看评论内容

#NIV#

Thorac Cancer：回顾性分析使用nivolumab治疗获得长期生存的NSCLC患者的相关因素

2022-01-28

tamgche (审核中...)

前往app查看评论内容

#NIV#

ASCO：NIVO+RELA相较NIVO能更好的的改善既往未经治疗的转移性或不可切除性黑色素瘤患者

2022-08-30

tamgche (审核中...)

前往app查看评论内容

#NIV#

Eur Urol：化放疗联合Nivolumab±Ipilimumab治疗肌层浸润性膀胱癌的安全性评估

2023-04-10

tamgche (审核中...)

前往app查看评论内容

#NIV#

Clin Cancer Res：术前和术后应用nivolumab和lirilumab治疗局部区域复发的头颈部鳞状细胞癌(SCCHN)患者的疗效和安全性

2022-03-28

tamgche (审核中...)

前往app查看评论内容

#NIV#

2022 ASCO：RP1+nivo治疗皮肤癌的疗效与安全性——IGNYTE研究的最新结果

2023-01-19

tamgche (审核中...)

前往app查看评论内容

#NIV#

Eur Urol Focus：Nivolumab单药治疗晚期肾细胞癌的疗效如何？

2022-06-05

tamgche (审核中...)

前往app查看评论内容

#NIV#

Eur Urol：Bempegaldesleukin加Nivolumab用于一线转移性尿路上皮癌效果如何？

2023-05-24

tamgche (审核中...)

前往app查看评论内容

#NIV#

Ann Oncol：一线nivolumab + ipilimumab vs化疗治疗不可切除的恶性胸膜间皮瘤的疗效:CheckMate 743的3年生存结果

2022-10-16

tamgche (审核中...)

前往app查看评论内容

#NIV#

FDA批准LAG-3抗体Relatlimab联合Nivolumab用于不可切除或转移性黑色素瘤的儿童和成人患者

2022-07-15

tamgche (审核中...)

前往app查看评论内容

#NIV#

Clin Cancer Res：Nivolumab对比卡铂+培美曲塞治疗EGFR突变NSCLC患者一线TKI治疗进展后的疗效

2022-07-23

tamgche (审核中...)

前往app查看评论内容

#NIV#

Clin Cancer Res：nivolumab + ipilimumab对比舒尼替尼治疗晚期肾细胞癌（aRCC）患者后的无治疗生存时间（TFS）对比：来自Check- Mate 214研究结果

2021-12-18

tamgche (审核中...)

前往app查看评论内容

#NIV#

NEJM：bamlanivimab-etesevimab双中和抗体疗法治疗轻中度新冠肺炎

2021-08-31

tamgche (审核中...)

前往app查看评论内容

#NIV#

J Immunother Cancer：CheckMate 920研究评估nivolumab(那武利尤单抗)+ ipilimumab (伊匹木单抗)治疗晚期非透明细胞肾癌患者的疗效和安全性

2022-10-24

仁医06 (审核中...)

前往app查看评论内容

#NIV#

Ann Oncol：局限期小细胞肺癌(LD-SCLC)患者同步放化疗+PCI后使用nivolumab+ipilimumab免疫联合强化治疗并不能改善患者的预后

2022-01-06

tamgche (审核中...)

前往app查看评论内容

#NIV#

J Immunother Cancer：黑素瘤脑转移(MBMs)患者一线BRAF- MEKi耐药后使用ipilimumab- nivolumab治疗效果差

2022-09-25

tamgche (审核中...)

前往app查看评论内容

#NIV#

Lung Cancer: 纳武利尤单抗（nivolumab）治疗既往治疗过的晚期NSCLC患者的2年生存：来自法国、德国和加拿大的真实世界研究

2021-09-01

tamgche (审核中...)

前往app查看评论内容

#NIV#

Ann Oncol: 纳武利尤单抗（Nivolumab）二线治疗并不能改善小细胞肺癌的预后：来自CheckMate 331临床研究

2021-10-12

tamgche (审核中...)

前往app查看评论内容

#NIV#

J Immunother Cancer：Nivolumab(那武利尤单抗)联合cabozantinib(卡博替尼)治疗晚期子宫内膜癌患者的疗效

2022-08-01

tamgche (审核中...)

前往app查看评论内容

#NIV#

Eur Urol：Nivolumab治疗转移性肾细胞癌的患者的原发性肾肿瘤反应

2022-05-13

tamgche (审核中...)

前往app查看评论内容

#NIV#

Clin Cancer Res：ATTRACTION-3研究3年随访生存结果表明nivolumab较化疗改善晚期食管鳞状细胞癌（ESCC）患者预后

2023-01-06

科室
- - 订阅+
  - 更多科室
工具
服务